⚡PATHFINDER 2 trial results for a multi-cancer early-detection blood test were published, reporting safety and performance data.

What it means

The PATHFINDER 2 trial results, published in Nature Medicine, evaluate the safety and performance of Grail's Galleri multi-cancer early-detection (MCED) blood test. This prospective, interventional study measures how well the test detects cancer signals from cell-free DNA and pinpoints the likely origin of the cancer, demonstrating high specificity and positive predictive value, with most screen-detected cancers found at early stages – including types for which no standard screening exists.

Accuracy & sourcesSourced

This is a direct primary source: the peer-reviewed paper in Nature Medicine (doi:10.1038/s41591-026-04618-w). The claim's solidity is high; the reported metrics (specificity, PPV, stage distribution) come from the trial data itself, though independent replication is not yet available.

How new